{"links":{"html":"https://www.erudio.com/reports/extend-op-nct06367972","json":"https://www.erudio.com/reports/extend-op-nct06367972.json","markdown":"https://www.erudio.com/reports/extend-op-nct06367972.md","mcp":{"server":"https://mcp.erudio.com/free","tool":"get_report_card","arguments":{"slug":"extend-op-06367972"}},"request":"https://www.erudio.com/contact?report=extend-op-06367972"},"offer":{"cited_commentary_sources":3,"verified_hcp_statements":25,"currency":"USD","delivery":{"checkout":"online","current_edition":"Emailed as soon as payment clears: downloads, a license key and a prompt that connects your AI agent through Erudio MCP. One key per email address holds every report bought with it.","refresh":"A purchase starts a check for new commentary. A new edition, if one results, is sent to the buyer at no charge."},"identities":{"adds":"Verified IDs for the clinicians in the report, led by the NPI, so a Medical Affairs team can connect the report's voices to the expert and insight records it keeps by NPI: also X, Bluesky, LinkedIn and web pages, ORCID and OpenAlex where verified, inline on each person card (identifiers.status included). Without the add-on, each card's identifiers.status says whether the person is verified. For scientific and insight use inside the organization, including non-promotional engagement such as advisory boards and scientific exchange under its own compliance process; not for promotional targeting. Every report already names and describes its speakers and includes CMS-reported financial relationships. Sample: https://www.erudio.com/report-sample.json","available_with":"12-month updates","cap_usd":750,"identity_verified_people":4,"optional":true,"price_per_verified_person_usd":15,"price_usd":60,"product":"updates-12-identities","terms":"Priced on the identity-verified people in the edition at purchase; people verified later in the term come at no charge."},"one_off_usd":750,"purchase":{"agents":{"free_mcp":"https://mcp.erudio.com/free","keys":"One license key holds every report: get_order returns it once paid (store it as a secret), send it as licence_key with every later create_order so new reports join it. The buyer gets their account key by email, which reads every report bought with their address; recover_key (POST /api/keys/recover) with the buyer's email sends it again.","mcp_flow":["1. search_reports: Find reports by trial, NCT ID, drug, indication or sponsor. Each result has its page URL and price.","2. get_report_card: Preview one report with the slug from search_reports: what it covers, its findings and limits, and the price of each product.","3. create_order: Order the current edition or weekly updates for your person. It returns the quote, a checkout_url for your person to pay by card and, when offered, a pay_url your own payment client can pay over HTTP 402 (MPP or x402). Nothing is charged until one is paid.","4. get_order: Once the order is paid, it returns the license key. Store the key as a secret and send it as licence_key with every later create_order, so one key holds every report.","5. read_report: Read the report in full or by section on https://mcp.erudio.com/mcp, with the key as Authorization: Bearer. get_report_changes shows what a newer edition changed."],"order_endpoint":"https://www.erudio.com/api/orders","order_request":{"buyer_email":"name@company.com","idempotency_key":"optional, one per purchase","licence_key":"optional: your key from an earlier purchase","organization":"optional","product":["edition","updates-3","updates-6","updates-12","updates-12-identities"],"report":"extend-op-nct06367972"},"steps":"Create the order (with licence_key if you hold one) and show checkout_url to your person to pay by card. If the order also returns pay_url, you can pay it yourself instead: POST pay_url answers 402 Payment Required with MPP or x402 offers for your payment client. Once paid, status_url (or get_order) returns the license key, the MCP setup and downloads."},"contact":{"email":"hello@erudio.com","form":"https://www.erudio.com/contact?report=extend-op-06367972","people":"Audun Utengen and Tom Lee, the founders","use_for":"Questions, invoices, purchase orders"},"methods":["card (Stripe Checkout)"],"people":"https://www.erudio.com/reports/extend-op-nct06367972","renewal":"Subscriptions are prepaid and do not renew automatically.","upgrades":"What the buyer already paid on this trial counts toward a longer plan: a one-off edition within 30 days, or an active plan at any time in its term. The buyer pays the difference; an upgraded plan keeps its original start, and an upgraded one-off starts the plan on payment. Order the longer product with create_order and the buyer's licence_key (or on the report page with the buyer's email); the quote shows the credit.","terms":"https://www.erudio.com/terms"},"size":"focused","size_rule":"Focused: 1–150 verified statements","updates_usd":{"3_months":1300,"6_months":1900,"12_months":2600},"volume_discounts":[{"min_subscribed_trials":10,"percent_off_updates":25},{"min_subscribed_trials":5,"percent_off_updates":15}]},"publication_state":"public","record":{"change":{"changed_finding_ids":{"reason":"No changed finding IDs recorded.","status":"none"},"last_checked_at":"2026-11-01T15:37:02.649557Z","notify_subscribers":false,"status":"new","summary":{"reason":"First accepted edition: there is no earlier edition to compare.","status":"not_applicable"}},"contents":{"aspect_coverage":{"assessment_incomplete":0,"discussed":8,"no_commentary_found":0},"aspects":[{"claim_count":6,"coverage":"discussed","id":"T1","registry_field":"outcomesModule.primaryOutcomes[0]","source_count":1,"title":"Primary endpoint: Safety and adverse events (AEs)"},{"claim_count":9,"coverage":"discussed","id":"T2","registry_field":"conditionsModule","source_count":2,"title":"Population and setting"},{"claim_count":9,"coverage":"discussed","id":"T3","registry_field":"armsInterventionsModule.armGroups","source_count":2,"title":"The comparison"},{"claim_count":1,"coverage":"discussed","id":"T4","registry_field":"outcomesModule","source_count":1,"title":"Safety and tolerability"},{"claim_count":5,"coverage":"discussed","id":"T5","registry_field":"designModule","source_count":3,"title":"Design and conduct"},{"claim_count":9,"coverage":"discussed","id":"A1","source_count":1,"title":"CURB, RADIANT and AVATAR: selective breast-cancer line preservation"},{"claim_count":4,"coverage":"discussed","id":"A2","source_count":1,"title":"Value of deferring next-line therapy and the alternative add-on question"},{"claim_count":2,"coverage":"discussed","id":"A3","source_count":2,"title":"Patient-centered endpoints"}],"counts":{"cited_sources":4,"claims_by_expression_type":{"comparison":1,"interpretation":3,"opinion":5,"primary_context":3,"question":2,"restatement":6,"uncertainty":1,"unspecified":4},"claims_by_kind":{"interpretation":1,"protocol_statement":3,"source_observation":21},"clinician_statements":15,"evidence_units":20,"findings":4,"people_cited":4,"people_identity_verified":4,"people_total":5,"screened_sources":6,"verified_claims":25},"findings_index":[{"id":"F1","structure":{"claims":10,"claims_by_group":{"comparisons":0,"experience":0,"questions":3,"restated":5,"views":2},"has_counterview":false,"limitations":3,"links":{"context":4,"support":10},"ma_question":true,"named_voices":2,"passages":9,"sources":2,"sources_by_kind":{"commentary":1,"registry":1}},"title":"The PFS objection became acceptance after the treatment sequence was clarified"},{"id":"F2","structure":{"claims":5,"claims_by_group":{"comparisons":0,"experience":0,"questions":1,"restated":1,"views":3},"has_counterview":false,"limitations":3,"links":{"context":0,"support":6},"ma_question":true,"named_voices":1,"passages":3,"sources":2,"sources_by_kind":{"commentary":1,"registry":1}},"title":"Deferring the next systemic line was valued conditionally, not equated with superior PFS"},{"id":"F3","structure":{"claims":10,"claims_by_group":{"comparisons":1,"experience":0,"questions":0,"restated":6,"views":3},"has_counterview":false,"limitations":3,"links":{"context":0,"support":12},"ma_question":true,"named_voices":2,"passages":7,"sources":1,"sources_by_kind":{"commentary":1}},"title":"Breast-cancer support for line preservation was selective and qualified by contrasting studies"},{"id":"F4","structure":{"claims":3,"claims_by_group":{"comparisons":0,"experience":0,"questions":0,"restated":1,"views":2},"has_counterview":false,"limitations":2,"links":{"context":0,"support":3},"ma_question":true,"named_voices":1,"passages":3,"sources":2,"sources_by_kind":{"commentary":2}},"title":"Investigator enthusiasm concerned patient-centered evidence and colorectal accrual, not demonstrated benefit"}],"medical_affairs_question":"How should Medical Affairs distinguish treatment-delay value from benefit through the next systemic line, while preserving toxicity and patient-selection caveats?","sections":{"analysis":[{"id":"section-1","level":3,"title":"The PFS objection was answered by clarifying which progression counts"},{"id":"section-2","level":3,"title":"Preserving a systemic line is a different value proposition from outperforming the next line"},{"id":"section-3","level":3,"title":"Breast-cancer evidence was interpreted through timing, burden and selection"},{"id":"section-4","level":3,"title":"Enthusiasm focused on patient-centered evidence and completion of colorectal recruitment"},{"id":"section-5","level":3,"title":"Scope and coverage"}],"executive_summary":{"reason":"Reviewed narrative has no headings.","status":"unavailable"}},"study_design":"interventional, randomized, single group, phase2, phase3","trial_dimensions":[{"findings":[{"id":"F1","shared_claims":6},{"id":"F2","shared_claims":1}],"id":"T1","label":"Primary endpoint: Safety and adverse events (AEs)"},{"findings":[{"id":"F1","shared_claims":2},{"id":"F3","shared_claims":6},{"id":"F4","shared_claims":1}],"id":"T2","label":"Population and setting"},{"findings":[{"id":"F1","shared_claims":6},{"id":"F2","shared_claims":4},{"id":"F3","shared_claims":1},{"id":"F4","shared_claims":1}],"id":"T3","label":"The comparison"},{"findings":[{"id":"F2","shared_claims":1},{"id":"F3","shared_claims":1}],"id":"T4","label":"Safety and tolerability"},{"findings":[{"id":"F1","shared_claims":2},{"id":"F4","shared_claims":3}],"id":"T5","label":"Design and conduct"}]},"identity":{"accepted_at":"2026-11-01T15:37:02.649557Z","edition_number":1,"previous_run_id":{"reason":"First accepted catalog edition.","status":"not_applicable"},"previous_version":{"reason":"First accepted catalog edition.","status":"not_applicable"},"product_contract":"hcp-commentary-1","published_at":"2026-11-01T15:47:17Z","record_hash":"9e80af3a20a507ade82890636888b34b877ec4a084485e94684630f38c3e32a4","release_hash":"283729854d3e357ff13eeea697a0772d4e45a385f0fd9f58cd4167ed961ad6fa","report_id":"erudio-nct06367972","run_id":"f8caa876-d285-479a-8c00-bc9d6b630b96","schema_version":"5.0","slug":"extend-op-06367972","version":"1.0.0","version_reason":"initial"},"offer":{"bundle_eligible":{"reason":"Owner has not set bundle_eligible.","status":"not_set"},"license_ref":{"reason":"Owner has not set license_ref.","status":"not_set"},"request_route":{"reason":"Owner has not set request_route.","status":"not_set"},"single_edition":{"reason":"Owner has not set single_edition.","status":"not_set"},"updates":{"reason":"Owner has not set updates.","status":"not_set"}},"preview":{"abstract":"EXTEND-OP compares local consolidation with next-line systemic therapy in oligoprogressive metastatic disease; sequencing clarification resolved a speaker’s progression-free survival objection. The report cites three radiation oncologists, including a speaker described in the source as a principal investigator. Further debate concerns when deferring next-line systemic therapy has value and which breast-cancer patients might benefit from line preservation. How should treatment delay be distinguished from benefit through the next systemic line, while keeping toxicity and patient selection in view?","meta_description":"6 sources screened · 25 verified statements (15 from clinicians verified by NPI or staff page) from 4 sources · 4 findings. Updated Nov 1, 2026.","person_names_policy":"role_only","sample_findings":[{"cited_claim_ids":["claim-763f08f481d699754572","claim-4585e605355c90a7fa1f","claim-2691111fa65cd9524de8","claim-ebe90bda89e516db4212","claim-d00f8d77b9f8a0d9628a","claim-92284ad2c93c46e9623e"],"id":"F1","paraphrase":"An X-thread discussion asked how progression-free survival is assessed across the EXTEND-OP treatment sequence.","publication_caveats":["The questioner’s clinical role is not stated in the sources reviewed for this edition.","The registry’s endpoint descriptions differ; no full protocol or results publication was available in the sources reviewed for this edition."],"source_channel":"x_thread","source_date":"2025-10-01","title":"The PFS objection became acceptance after the treatment sequence was clarified"}]},"publication":{"approved_at":"2026-11-01T15:47:17Z","approved_by":"Erudio publisher","corrections":[],"rights_status":"cleared: short attributed excerpts with link-out; no-derivatives sources suppressed; role-only names in previews","state":"public"},"schema_id":"erudio.catalog_record","schema_version":"2.1","scope_and_limits":{"commentary_scope":{"basis":"Only the sources used in this report; not all HCPs or all public discussion.","has_known_gaps":true,"source_count":6},"does_not":["judge efficacy","estimate HCP prevalence or consensus","give treatment advice"],"known_gaps":["Discussion that does not name the trial may be missing from this edition.","Some passages in the sources used in this report were not fully assessed for clinician views, so a view there may be missing from this edition.","10 statements in the sources reviewed for this edition are about other patients or topics, or only mention the trial, and are not counted.","Further source limits apply, so some matching discussion may be missing.","The sources reviewed for this edition do not represent all HCP discussion or establish consensus. Some potentially relevant discussion was not fully assessed, and comments that did not name the trial or used other name variants may be missing.","Some speakers' identities or clinical roles are not established in the sources used in this report; each statement is attributed only as far as its source shows.","The CURB, RADIANT and AVATAR figures remain attributed to a speaker’s summaries. Comparisons across these studies do not establish causal effects of earlier treatment, fewer lesions or a particular selection strategy.","A speaker, described in the source as a principal investigator of EXTEND-OP, discussed anticipated evidence and completed colorectal recruitment. These statements do not establish clinical benefit, safety or recruitment status across every EXTEND-OP cohort."]},"sources":{"cited_sources":{"by_channel":{"bluesky_thread":0,"linkedin_post":0,"other":0,"podcast":0,"publication":0,"registry":1,"regulatory":0,"x_thread":3,"x_video":0,"youtube":0},"by_evidence_role":{"commentary":3,"methods":1},"count":4,"evidence_window":{"end":"2026-10-09","start":"2025-10-01"},"retrieval_snapshot":"2026-11-01T14:55:13.652745Z","timeline":[{"count":1,"week":"2025-W40"},{"count":1,"week":"2026-W18"},{"count":1,"week":"2026-W41"}],"undated_sources":1},"quote_policies":[{"id":"clinicaltrials:NCT06367972:methods","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1840391836189237325:c90497a9-c8cd-4051-b905-89a1ea5ab5c3","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1943492536019948013:3f00b3a7-fdbd-45ab-86bc-0fcfdd7df41f","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1973460578615349693:97fe13a8-b2e2-4d6c-b752-3f736d4654f0","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2049284412076896589:ed274636-1bba-4997-88f9-b64dd8b0166d","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2067343133151567916:006c6fe4-162b-44e3-a112-17508a3ee69b","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2108685246883402237:22a6fe1e-ab36-49f8-930b-fe3ff79050a5","quote_policy":"short_quote_link_out"}],"screened_sources":{"by_channel":{"bluesky_thread":0,"linkedin_post":0,"other":0,"podcast":0,"publication":0,"registry":0,"regulatory":0,"x_thread":6,"x_video":0,"youtube":0},"by_evidence_role":{"commentary":6},"count":6,"evidence_window":{"end":"2026-10-09","start":"2024-09-29"},"retrieval_snapshot":"2026-11-01T14:55:13.652745Z","timeline":[{"count":1,"week":"2024-W39"},{"count":1,"week":"2025-W28"},{"count":1,"week":"2025-W40"},{"count":1,"week":"2026-W18"},{"count":1,"week":"2026-W25"},{"count":1,"week":"2026-W41"}],"undated_sources":0}},"taxonomy":{"biomarkers":{"reason":"No structured, checked-in biomarker mapping for this trial.","status":"unmapped"},"conferences":{"reason":"No conferences in source metadata.","status":"none"},"drugs":{"reason":"Registry lists no drug interventions.","status":"not_applicable"},"indications":[{"reason":"Unmapped registry condition: OligoProgressive Metastatic Disease","status":"unmapped"}],"line_of_therapy":{"reason":"No structured, checked-in line-of-therapy mapping for this trial.","status":"unmapped"},"therapeutic_area":{"reason":"Conditions lack a therapeutic-area mapping.","status":"unmapped"}},"trial":{"acronym":"EXTEND-OP","aliases":["EXTEND-OP","A Randomized Phase II Basket Trial EXTENDing Efficacy of Systemic Therapy With Local Consolidative Therapy for OligoProgressive Metastatic Disease (EXTEND-OP)"],"brief_title":"A Randomized Phase II Basket Trial EXTENDing Efficacy of Systemic Therapy With Local Consolidative Therapy for OligoProgressive Metastatic Disease (EXTEND-OP)","collaborators":{"reason":"Not present in the acquired registry snapshot.","status":"unavailable"},"conditions":["OligoProgressive Metastatic Disease"],"display_condition":"oligoprogressive metastatic disease","display_interventions":[],"enrollment":{"count":400,"type":"ESTIMATED"},"interventions":[{"name":"Local Consolidation Therapy","synonyms":["LCT"],"type":"PROCEDURE"},{"name":"Next-line Systemic Therapy","synonyms":["NLST"],"type":"PROCEDURE"}],"nct_id":"NCT06367972","official_title":"A Randomized Phase II Basket Trial EXTENDing Efficacy of Systemic Therapy With Local Consolidative Therapy for OligoProgressive Metastatic Disease (EXTEND-OP)","overall_status":"RECRUITING","phase":["PHASE2","PHASE3"],"primary_completion_date":{"date":"2028-10-10","type":"ESTIMATED"},"primary_endpoints":[{"description":"Incidence of Adverse Events, Graded According to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) Version (v) 5.0","measure":"Safety and adverse events (AEs)","timeFrame":"Through study completion; an average of 1 year."}],"registered_date":{"date":"2024-04-16","type":"ACTUAL"},"registry_last_updated":"2026-06-11","registry_url":"https://clinicaltrials.gov/study/NCT06367972","short_name":"EXTEND-OP","short_name_basis":"canonical_name","sponsor":"M.D. Anderson Cancer Center","start_date":{"date":"2024-06-06","type":"ACTUAL"},"study_design":"interventional, randomized, single group, phase2, phase3","study_ids":[{"id":"2024-0070","type":"sponsor_study_id"},{"domain":"NCI-CTRP Clinical Registry","id":"NCI-2024-03278","type":"other"}],"study_type":"INTERVENTIONAL"}}}